Patent DE878856C successfully refreshed from Google Patents.
US5597897A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical formulations of osteogenic proteins
Assignee: Genetics Institute LLC
•
Filing: 1992-06-22
•
Granted: 1997-01-28
•
Expires: 2012-06-22
Abstract
Abstract A composition comprising a pharmaceutically acceptable admixture of an osteogenic protein; a polymer matrix component selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid; and an osteogenic protein-sequestering material.
Inventors
- 👤 Eyal Ron
- 👤 Thomas J. Turek
- 👤 Benjamin S. Isaacs
- 👤 Himakshi Patel
- 👤 Richard A. Kenley
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 22:56
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0024; A61K38/00; A61K38/16; A61K38/17; A61K38/18; A61K38/1875; A61K9/14; A61K9/16; A61K9/1605; A61K9/1617; A61K9/1629; A61K9/1641; A61K9/1647; A61K9/1652; A61L; A61L27/00; A61L27/14; A61L27/22; A61L27/227; A61P; A61P19/00; A61P19/08; A61P19/10; A61P43/00; A61F; A61F2/00; A61F2/02; A61F2/28
Claims Analysis
Total Claims: 30
Claim 1
Independent Claim
70 words
A composition comprising a pharmaceutically acceptable admixture of (i) an ostcogenic protein; (ii) a polymer matrix component selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid; and (iii) an osteogenic protein-sequestering alkylcellulose, wherein said alkylcellulose is present in an amount of approximately 0.5-20 wt % based on total composition weight, wherein said osteogenic protein is not encapsulated within the polymer matrix.
Claim 2
Dependent Claim
70 words
A composition comprising a pharmaceutically acceptable admixture of (i) an ostcogenic protein; (ii) a polymer matrix component selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid; and (iii) an osteogenic protein-sequestering alkylcellulose, wherein said alkylcellulose is present in an amount of approximately 0.5-20 wt % based on total composition weight, wherein said osteogenic protein is not encapsulated within the polymer matrix.
Claim 3
Dependent Claim
21 words
The composition of claim 1 wherein the osteogenic protein is selected from the group consisting of the members of the BMP-family.
Claim 4
Dependent Claim
11 words
The composition of claim 2 wherein the osteogenic protein is BMP-2.
Claim 5
Dependent Claim
15 words
The composition of claim 2 wherein the cellulosic material is selected from hydroxypropylmethylcellulose and carboxymethylcellulose.
Claim 6
Dependent Claim
15 words
The composition of claim 3 wherein the cellulosic material is selected from hydroxypropylmethylcellulose and carboxymethylcellulose.
Claim 7
Dependent Claim
19 words
The composition of claim 5, wherein the polymer matrix component is a copolymer of lactic acid and glycolic acid.
Claim 8
Dependent Claim
106 words
A composition comprising a pharmaceutically acceptable admixture of (i) BMP-2; (ii) a polymeric matrix component comprising polymeric particles having a diameter of between about 150 and 850 microns and a porosity such that the surface area of the particles is between about 0.02 and 4 m 2 /g, wherein the polymer is selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid; and (iii) a protein sequestering amount of carboxymethylcellulose, wherein said carboxymethylcellulose is present in an amount of approximately 0.5-20 wt % based on total composition weight, wherein said BMP-2 is not encapsulated within the polymeric matrix.
Claim 9
Dependent Claim
106 words
A composition comprising a pharmaceutically acceptable admixture of (i) BMP-2; (ii) a polymeric matrix component comprising polymeric particles having a diameter of between about 150 and 850 microns and a porosity such that the surface area of the particles is between about 0.02 and 4 m 2 /g, wherein the polymer is selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid; and (iii) a protein sequestering amount of carboxymethylcellulose, wherein said carboxymethylcellulose is present in an amount of approximately 0.5-20 wt % based on total composition weight, wherein said BMP-2 is not encapsulated within the polymeric matrix.
Claim 10
Dependent Claim
11 words
The composition of claim 1 wherein the osteogenic protein is TGF-β.
Claim 11
Dependent Claim
11 words
The composition of claim 1 wherein the osteogenic protein is Vgr-1.
Claim 12
Dependent Claim
11 words
The composition of claim 1 wherein the osteogenic protein is OP-1.
Claim 13
Dependent Claim
15 words
The composition of claim 1 wherein the osteogenic protein is selected from COP-5 and COP-7.
Claim 14
Dependent Claim
43 words
A composition consisting essentially of a pharmaceutically acceptable admixture of (i) an osteogenic protein; (ii) a polymer matrix component selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid; and (iii) an osteogenic protein-sequestering alkylcellulose.
Claim 15
Dependent Claim
43 words
A composition consisting essentially of a pharmaceutically acceptable admixture of (i) an osteogenic protein; (ii) a polymer matrix component selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid; and (iii) an osteogenic protein-sequestering alkylcellulose.
Claim 16
Dependent Claim
17 words
The composition of claim 12 wherein the polymer matrix component is in the form of porous particles.
Claim 17
Dependent Claim
17 words
The composition of claim 9 wherein the polymer matrix component is in the form of porous particles.
Claim 18
Dependent Claim
21 words
The composition of claim 12 wherein the osteogenic protein is selected from the group consisting of the members of the BMP-family.
Claim 19
Dependent Claim
11 words
The composition of claim 15 wherein the osteogenic protein is BMP-2.
Claim 20
Dependent Claim
15 words
The composition of claim 16 wherein the cellulosic material is selected from hydroxypropylmethylcellulose and carboxymethylcellulose.
Claim 21
Dependent Claim
19 words
The composition of claim 17, wherein the polymer matrix component is a copolymer of lactic acid and glycolic acid.
Claim 22
Dependent Claim
17 words
The composition of claim 18 wherein the polymer matrix component is in the form of porous particles.
Claim 23
Dependent Claim
17 words
The composition of claim 17 wherein the polymer matrix component is in the form of porous particles.
Claim 24
Dependent Claim
17 words
The composition of claim 16 wherein the polymer matrix component is in the form of porous particles.
Claim 25
Dependent Claim
15 words
The composition of claim 15 wherein the cellulosic material is selected from hydroxypropymethylcellulose and carboxymethylcellulose.
Claim 26
Dependent Claim
17 words
The composition of claim 22 wherein the polymer matrix component is in the form of porous particles.
Claim 27
Dependent Claim
17 words
The composition of claim 12 wherein the osteogenic protein is selected from TGF-β, Vgr-1, COP-5 and COP-7.
Claim 28
Dependent Claim
11 words
The composition of claim 12 wherein the osteogenic protein is OP-1.
Claim 29
Dependent Claim
80 words
A composition consisting essentially of a pharmaceutically acceptable admixture of (i) BMP-2; (ii) a polymeric matrix component comprising polymeric particles having a diameter of between about 150 and 850 microns and a porosity such that the surface area of the particles is between about 0.02 and 4 m 2 /g, wherein the polymer is selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid; and (iii) a protein sequestering amount of carboxymethylcellulose.
Claim 30
Dependent Claim
80 words
A composition consisting essentially of a pharmaceutically acceptable admixture of (i) BMP-2; (ii) a polymeric matrix component comprising polymeric particles having a diameter of between about 150 and 850 microns and a porosity such that the surface area of the particles is between about 0.02 and 4 m 2 /g, wherein the polymer is selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid; and (iii) a protein sequestering amount of carboxymethylcellulose.
References Cited (Backward Citations)
US3407076A
Cited
GB1332505A
Cited
US3991766A
Cited
US4033938A
Cited
EP0140255A2
Cited
US4917893A
Cited
EP0145240A2
Cited
US4818542A
Cited
US4563489A
Cited
US4637931A
Cited
US4954298A
Cited
US4933182A
Cited
WO1988000205A1
Cited
US4877864A
Cited
US5053485A
Cited
EP0330180A1
Cited
WO1989010409A1
Cited
WO1989009788A2
Cited
US5108753A
Cited
WO1990009783A1
Cited
US4975526A
Cited
WO1990015586A2
Cited
CA2024196A1
Cited
WO1992000718A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-01-28 | 2000-07-29 | 2001-01-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-01-28 | 2004-07-29 | 2005-01-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-01-28 | 2008-07-29 | 2009-01-28 | $7700.00 | Window Closed / Lapsed |